Tech Company Financing Transactions

Fore Biotherapeutics Funding Round

Medicxi Ventures, SR One Capital Management and 3B Future Health Fund participated in a $75 million Series D venture round for Fore Biotherapeutics. The round was announced on 8/25/2023.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3675 Market Street 200
Philadelphia, PA 19104
USA

Phone

(267) 641-7575

Website

www.fore.bio

Email Address

[email protected]

Overview

We are a precision oncology company using functional genomics to pioneer treatments that improve the lives of patients with rare cancers. Fore Bio is a next-generation precision oncology company. Using our functional genomics platform, we are hyper-targeting therapies to unaddressed tumor mutations to benefit patients with few therapeutic alternatives. Our mission is to provide "1-to-1" matching between patients and new treatments tailored to them and providing broad access with speed and quality.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Matthew Ros

        

Chief Financial Officer

Jeff Sacher

        

Chief Medical Officer

Stacie Shepherd

        

Chief Technical Officer

Gabi Tarcic

        

Browse more venture capital transactions:

Prev: 8/25/2023: Dripl venture capital transaction
Next: 8/25/2023: Metroc venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary